The meningitis diagnostic testing market size is estimated to be USD 1,46.83 million in 2022 and is expected to witness a CAGR of 4.31% during the forecast period 2023-2033. Rising prevalence of meningitis, supportive government initiatives, and growing preference for point-of-care testing are some of the factors projected to drive the market growth in near future. Furthermore, ongoing research projects around the world and different organic and inorganic initiatives made by major industry players However, lack of awareness is predicted to limit market growth.

Ongoing research projects around the world is expected to fuel the market growth during the forecast period. For instance, scientists from Imperial College London were awarded a USD 23.5 million funding from the EU in February 2020 for the development and commercialization of a meningitis fast diagnostic test across Europe. The personalized gene signatures to diagnose severe disease are the most cutting-edge component of this investigational test.

Different organic and inorganic initiatives made by major industry players is predicted to propel the market growth during the projected period. For instance, in January 2022, QIAGEN reported advances in the marketing of its QIAstat-Dx syndromic diagnostic product. Hospitals and laboratories may now screen several pathogens from a single sample thanks to the improvement. Additionally, this new test makes it possible to differentiate between GI pathogens and meningitis infections.

Segmentation

 By Test Type

The market is categorized into lateral flow assay, latex agglutination tests, ELISA tests, culture test, PCR assay, and others. In 2022, the PCR assay segment accounted for the highest revenue share due to the availability of a wide range of PCR tests and the widespread use of PCR assays for meningitis detection due to their high accuracy. The popularity of PCR tests for meningitis testing is also projected to expand due to their better sensitivity and the delivery of data that are extremely precise and accurate. The commercial availability of numerous RT-PCR platforms, including single-target (singleplex) detection tests and multi-target (multiplex) detection tests that offer results in less than two hours, is also boosting the use of PCR assays. Additionally, the segment is anticipated to benefit from technology developments in PCR assays that shorten turnaround times and support accurate diagnosis. For instance, the bioMerieux SA-developed BIOFIRE FILMARRAY ME PANEL enables precise and rapid testing for common pathogens that result in a number of CNS infections.

 By End User

The market is categorized into diagnostic centers, hospitals, and others. In the global market, the hospitals segment accounted for the largest revenue share in 2022 owing to Meningitis’ high prevalence, expanding healthcare coverage, improved accessibility to cutting-edge diagnostic tools, and affordability. The severity of the disease and rising meningitis hospitalization rates are anticipated to boost segment expansion over the projection period. Diagnostic centres represented the second-highest market share and are anticipated to expand at a profitable rate during the projection period. The primary drivers of category expansion are the rise in the incidence of infectious diseases and the rising use of technologically enhanced products for precise and accurate outcomes. The availability of a sizable number of diagnostic facilities that carry out meningitis diagnostic tests also contributes to the segment growth. For instance, UCSF Labs, ARUP Laboratories, and other diagnostic facilities provide meningitis diagnostic testing.

Regional Markets

In 2022, North America region accounted for the highest revenue in the meningitis diagnostic testing market and is expected to maintain its dominance during the forecast period. This is attributed to the presence of numerous top players in the region and the numerous strategic initiatives taken. Furthermore, throughout the projection period, region expansion is anticipated to be propelled by the high adoption rate of cutting-edge diagnostic technologies, the simplicity of obtaining diagnostic test kits, growing awareness of early diagnosis, and increase in the number of diagnostic facilities. Furthermore, in the upcoming years, a number of government efforts to support the identification of numerous infectious diseases are probably going to present profitable growth potential. Asia Pacific region is expected to experience the fastest growth over the forecast period. Some of the main drivers of the market growth are the rising incidence of meningitis, ongoing research, and expanding economies. Additionally, it is anticipated that ongoing trials in the region, beneficial government initiatives, and rising investments by regional market players will all boost region growth over the course of the forecasted period.

Competitor Insights

Some of the key players operating in the meningitis diagnostic testing market are Bio-Rad Laboratories, Abbott, Inc., Seegene Inc., ELITechGroup, IMMY, Thermo Fisher Scientific, Inc., Luminex Corporation, CERTEST BIOTEC, and Uniogen Oy.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

• For instance, Abacus Diagnostica introduced the GenomEra assay kit, a rapid PCR test, in Europe in July 2022 for the quick identification of viruses that cause meningitis and encephalitis. Additionally, BioFire Diagnostics launched the FilmArray ME panel in Taiwan in 2020 to simultaneously identify over 14 pathogens.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including test type and end user from 2022 to 2033.

Report Scope:

Segmentation: Meningitis Diagnostic Testing Market Report 2022 – 2033

Test Type (Revenue, USD Million), 2022 – 2033

• Lateral Flow Assay
• Latex Agglutination Tests
• ELISA Tests
• Culture Test
• PCR Assay
• Others

End user (Revenue, USD Million), 2022 – 2033

• Diagnostic Centers
• Hospitals
• Others

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA